DOCSLIB.ORG

Role of Clinical Pharmacologist in Healthcare- Present Scenario

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of Clinical Pharmacologist in Healthcare- Present Scenario Editorial Role of Clinical Pharmacologist in Healthcare- Present Scenario Dr. Farhan Ahmad Khan involved in the health sector, Clinical Pharmacologist play a Discovery of drugs as a therapeutic agent is one of the pivotal role in improving patient care, directly or indirectly, biggest achievement in the history of medical science. We can by promoting the safer and more effective use of drugs. This see that the mortality and morbidity due to different type of goal is achieved by conducting clinical trials, drug diseases has declined if we compare from the past. This is evaluations, and studies on Pharmacoepidemiology, possible because of the discovery of new drugs. This shows pharmacoeconomics, pharmacogenetics, pharmacovigilance the significance of the knowledge of application of drugs, its and clinical drug toxicology. These type of studies can also be mechanism, its contraindication. Misuse of drugs can lead to traced from the ancient times such as the discovery of drugs drug resistance, e.g in case of antibiotics its irrational use has such as quinine, reserpine and artemisinin, which were first lead to worldwide problem of Antibiotic Resistance. used as herbal medicines. Therefore, to combat the above drug related problems, a Several Nobel Prize laureates in medicine in the past can be branch of medical science was developed. Clinical considered as representatives of clinical pharmacological pharmacology is the scientific discipline that involves all research such as Sir John Vane, Sir James Black, George aspects of the relationship between drugs and humans. Harry Hitchings, Gertrude Elion and Arvid Carlsson. They all Gold in the early 1940s at Cornell was the person who first ‘practised’ clinical pharmacology during their efforts to introduced the name clinical pharmacology.[1,2] In addition, introduce new pharmacotherapeutics principles into clinical Paul Martini, professor of medicine in Bonn, published his medicine. monograph in 1932 entitled ‘Methodology of Therapeutic Investigation’ and he is considered by some as the first clinical Improvements in the health care were made possible because pharmacologist.[3] of the role of clinical Pharmacologists responsible for the development of new and innovative medicines. Clinical Pharmacology can help variety of professionals including physicians, pharmacists, nurses and scientists in Roles of Clinical Pharmacologists many different disciplines. As different professionals are The endeavour of a Clinical Pharmacologist is to develop Access this article online methods and strategies that improve the quality of drug use in Quick Response Code Website: www.iabcr.org individual patients and patient populations. In the first WHO report on clinical pharmacology in 1970,[4] the section on research emphasized the need for studies that explored the Int Arch BioMed Clin Res. mechanisms of action of drugs and identified their 2016 Mar;2(1):1-2 pharmacokinetics in humans. Clinical drug evaluation and clinical trial Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 License Phases I–III (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial Clinical Pharmacologist are also involved in Phase I-IV use, reproduction and distribution of the work in any medium, provided the original work is properly cited. studies. Clinical pharmacologists have been the pioneers in introducing the RCT and in particular in introducing the For reprints contact: [email protected] placebo as control. RCTs is considered to be the gold standard for documenting the efficacy of drugs.[5] International Archives of BioMedical and Clinical Research | Jan-Mar 2016 | Vol 2 | Issue 1 1 | P a g e Editorial Therapeutic drug monitoring. Therapeutic drug Measures to be taken monitoring is a scientific medical technology where clinical 1. Mandatory set up of Drug and Therapeutic Committee in pharmacology has made major contributions. The the hospitals under the guidance of Clinical Pharmacologists. measurement of drug concentrations in blood or plasma that 2. There should be proper and reliable data for diseases burden will help in recommending targets ranges in plasma at which in a community. The disease burden is a major determinant of there is an optimal therapeutic effect or an increased risk of the amount and type of medicines required by a given ADRs. community, and this, in turn, determines the scale of clinical pharmacology services required to ensure rational use of these Pharmacovigilance or Post-Marketing Surveillance. medicines. Reporting of Adverse drug reactions actions is necessary to 3. Formulation and implementation of the policy for ‘rational know the safety profile of the drug. Clinical Pharmacologists use of medicines’. This is also emphasized in the WHO confirm the ADRs. recommendations that countries must encourage or ensure Drug utilization studies. Clinical pharmacologists play a more appropriate (rational) use of medicines by;[9,10] key role in drug utilization research, which can be defined as establishing a national drug regulatory authority, formulating an eclectic collection of descriptive and analytical methods standard treatment guidelines, selecting an essential and theories for the quantification, understanding and medicines’ list, enforcing continuing medical education, evaluation of the processes of prescribing, dispensing and promoting prescribing audit or accredited standard of health consumption of medicines. care, providing unbiased medical information through medicines information centres and national drug formularies Clinical care. Critical drug evaluation is the cornerstone for Rational Use of Medicine. Critical drug evaluation assists the Prof. (Dr.) Farhan Ahmad Khan MBBS, MD practicing physician in rating the strength of documentation Professor and HOD about efficacy, safety and cost-effectiveness for a specific Department of Pharmacology drug therapy as compared with alternative therapies. Teerthanker Mahaveer Medical College and Research Centre Corresponding Author: Present Scenario Prof. (Dr.) Farhan Ahmad Khan Pharmacologists in our set up are mainly involved in either Professor and HOD teaching or industry. They have not played an active role in Department of Pharmacology Teerthanker Mahaveer Medical College and Research the delivery of patient care. In addition, they have not been Moradabad, India. involved in deciding the national drug policy or in the Email: [email protected] planning of various health programmes. More active and REFERENCES purposeful interaction with clinicians in the daily deliver y of 1. Dollery CT. Clinical pharmacology the first 75 years and a view patient care is required. Therefore, there is not proper of the future. Br J Clin Pharmacol 2006;6:650–5. utilization of Clinical Pharmacologists in our set up. 2. Reidenberg MM. The discipline of clinical pharmacology. Clin Pharmacol Ther 1985;38:2–5. 3. Shelley JH, Baur MP. Paul Martini: the first clinical In 1986, Dr. Satoskar stated in his paper ‘The expanding role pharmacologist? Lancet 1999;353:870–3. of Pharmacologists in the Indian scene, “a pharmacologist can 4. Clinical Pharmacology. Scope, Organisation, Training. Report of contribute a lot, not only by doing research, but also by a WHO Study group. World Health Organ Tech Rep helping the government in formulating the drug policy, in Ser1970;446:5–21. 5. Rawlins MD. De orienting the teaching programmes so as to make the students Testimonio. http://www/rcplondon.ac.uk/pubs/contents/304df931 aware of the social responsibility, and in educating the -2ddc-4a54-894e-e0cdb03e84a5.pdf (last accessed on 10 March community regarding the use and the abuse of drugs so as to 2016). [6] 6. Satoskar RS. The expanding role of pharmacologists in the achieve better health care” Today, the pharmacologist, the changing Indian scene. J Postgrad Med 1986;32:111-4. physician, and the drug industry function independently 7. World Health Organization: World directory of medical schools. without necessary coordination and collaboration. A sound 2010, University of Copenhagen. The AVICENNA directory of knowledge of pharmacology is mandatory for doctors to medicine,http://www.who.int/hrh/wdms/en/, 8. Smith AJ: Unfinished business: clinical pharmacology and world rightly prescribe drugs for any disease. health. Int J Risk Safety Med. 2005, 17: 65-71. 9. World Health Organization: Promoting rational use of medicines: Clinical pharmacology with its emphasis on critical drug Core components. 2002, Geneva: WHO Policy Perspectives on evaluation, scientific methodology, drug development and Medicines,No.5,http://apps.who.int/medicinedocs/pdf/h3011e/ involvement in the work of drug and therapeutics committees h3011e.pdf. 10. World Health Organization: The World Medicines Situation is strategically positioned to bridge the knowledge gap 2011: Rational Use of Medicines. Edited by: Holloway K, van between stakeholders including patients, clinicians, Dijk L. 2011, Geneva: WHO,http://apps.who.int/medicinedocs/ pharmacists, administrators, politicians and pharmaceutical documents/s16874e/s16874e.pdf companies within and outside healthcare institutions.[7,8] How to cite this article: Khan FA. Role of Clinical Pharmacologist in Healthcare-Present Scenario. Int Arch BioMed Clin Res. 2016 Mar;2(1):1-2 Source of Support: Nil, Conflict of Interest: None declared International Archives of BioMedical and Clinical Research | Jan-Mar 2016 | Vol 2 | Issue 1 2 | P a g e .
Load more

Recommended publications
  • 書 名 等 発行年 出版社 受賞年 備考 N1 Ueber Das Zustandekommen Der
    書 名 等 発行年 出版社 受賞年 備考 Ueber das Zustandekommen der Diphtherie-immunitat und der Tetanus-Immunitat bei thieren / Emil Adolf N1 1890 Georg thieme 1901 von Behring N2 Diphtherie und tetanus immunitaet / Emil Adolf von Behring und Kitasato 19-- [Akitomo Matsuki] 1901 Malarial fever its cause, prevention and treatment containing full details for the use of travellers, University press of N3 1902 1902 sportsmen, soldiers, and residents in malarious places / by Ronald Ross liverpool Ueber die Anwendung von concentrirten chemischen Lichtstrahlen in der Medicin / von Prof. Dr. Niels N4 1899 F.C.W.Vogel 1903 Ryberg Finsen Mit 4 Abbildungen und 2 Tafeln Twenty-five years of objective study of the higher nervous activity (behaviour) of animals / Ivan N5 Petrovitch Pavlov ; translated and edited by W. Horsley Gantt ; with the collaboration of G. Volborth ; and c1928 International Publishing 1904 an introduction by Walter B. Cannon Conditioned reflexes : an investigation of the physiological activity of the cerebral cortex / by Ivan Oxford University N6 1927 1904 Petrovitch Pavlov ; translated and edited by G.V. Anrep Press N7 Die Ätiologie und die Bekämpfung der Tuberkulose / Robert Koch ; eingeleitet von M. Kirchner 1912 J.A.Barth 1905 N8 Neue Darstellung vom histologischen Bau des Centralnervensystems / von Santiago Ramón y Cajal 1893 Veit 1906 Traité des fiévres palustres : avec la description des microbes du paludisme / par Charles Louis Alphonse N9 1884 Octave Doin 1907 Laveran N10 Embryologie des Scorpions / von Ilya Ilyich Mechnikov 1870 Wilhelm Engelmann 1908 Immunität bei Infektionskrankheiten / Ilya Ilyich Mechnikov ; einzig autorisierte übersetzung von Julius N11 1902 Gustav Fischer 1908 Meyer Die experimentelle Chemotherapie der Spirillosen : Syphilis, Rückfallfieber, Hühnerspirillose, Frambösie / N12 1910 J.Springer 1908 von Paul Ehrlich und S.
    [Show full text]
  • Swedish Model of Developing Innovative Drugs: What Happened and Why?
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 4 Issue 1 January 2020 Short Communication Swedish Model of Developing Innovative Drugs: What Happened and Why? Jan Olof G Karlsson* Received: December 12, 2019 Division of Drug Research/Pharmacology, Linköping University, Linköping, Published: December 23, 2019 Sweden © All rights are reserved by Jan Olof G *Corresponding Author: Jan Olof G Karlsson, Division of Drug Research/ Karlsson. Pharmacology, Linköping University, Linköping, Sweden. DOI: 10.31080/ASPS.2020.04.0463 - cacious drugs. It has for example been an explosion in our un- American collaborator Sterling Winthrop wanted to add “physi- Still there are large medical needs that are not met with effi it came to the final formulation of Visipaque, Nycomed Imaging’s derstanding of cancer biology but our ability to translate these ological concentration of calcium ions” to it, apparently because it advances into therapies is poor [1]. To developing new drugs is, would sound god when promoting Visipaque. Almén together with a few other scientists realized that such a formulation would put theoretically as well as practically, integrity, creativity, engagement, patients, particularly during coronary angiography, in real danger however, far from an easy task. It demands scientific competence, responsibility and, not at least, critical thinking. - because of increased risk of ventricular fibrillation. The Manage - arguments but not Almén! Later on competitors argue but without cover and develop new drugs that met large medical needs, e.g., ment of Nycomed Imaging was ambivalent for Sterling Winthrop’s Before 1990, the Swedish pharma industry was efficient to dis any proof that Visipaque was more nephrotoxic than its forerun- terbutaline (Bricanyl), felodipin (Plendil), metoprolol (Seloken) ners.
    [Show full text]
  • History-Of-Movement-Disorders.Pdf
    Comp. by: NJayamalathiProof0000876237 Date:20/11/08 Time:10:08:14 Stage:First Proof File Path://spiina1001z/Womat/Production/PRODENV/0000000001/0000011393/0000000016/ 0000876237.3D Proof by: QC by: ProjectAcronym:BS:FINGER Volume:02133 Handbook of Clinical Neurology, Vol. 95 (3rd series) History of Neurology S. Finger, F. Boller, K.L. Tyler, Editors # 2009 Elsevier B.V. All rights reserved Chapter 33 The history of movement disorders DOUGLAS J. LANSKA* Veterans Affairs Medical Center, Tomah, WI, USA, and University of Wisconsin School of Medicine and Public Health, Madison, WI, USA THE BASAL GANGLIA AND DISORDERS Eduard Hitzig (1838–1907) on the cerebral cortex of dogs OF MOVEMENT (Fritsch and Hitzig, 1870/1960), British physiologist Distinction between cortex, white matter, David Ferrier’s (1843–1928) stimulation and ablation and subcortical nuclei experiments on rabbits, cats, dogs and primates begun in 1873 (Ferrier, 1876), and Jackson’s careful clinical The distinction between cortex, white matter, and sub- and clinical-pathologic studies in people (late 1860s cortical nuclei was appreciated by Andreas Vesalius and early 1870s) that the role of the motor cortex was (1514–1564) and Francisco Piccolomini (1520–1604) in appreciated, so that by 1876 Jackson could consider the the 16th century (Vesalius, 1542; Piccolomini, 1630; “motor centers in Hitzig and Ferrier’s region ...higher Goetz et al., 2001a), and a century later British physician in degree of evolution that the corpus striatum” Thomas Willis (1621–1675) implicated the corpus
    [Show full text]
  • ILAE Historical Wall02.Indd 10 6/12/09 12:04:44 PM
    2000–2009 2001 2002 2003 2005 2006 2007 2008 Tim Hunt Robert Horvitz Sir Peter Mansfi eld Barry Marshall Craig Mello Oliver Smithies Luc Montagnier 2000 2000 2001 2002 2004 2005 2007 2008 Arvid Carlsson Eric Kandel Sir Paul Nurse John Sulston Richard Axel Robin Warren Mario Capecchi Harald zur Hauser Nobel Prizes 2000000 2001001 2002002 2003003 200404 2006006 2007007 2008008 Paul Greengard Leland Hartwell Sydney Brenner Paul Lauterbur Linda Buck Andrew Fire Sir Martin Evans Françoise Barré-Sinoussi in Medicine and Physiology 2000 1st Congress of the Latin American Region – in Santiago 2005 ILAE archives moved to Zurich to become publicly available 2000 Zonismide licensed for epilepsy in the US and indexed 2001 Epilepsia changes publishers – to Blackwell 2005 26th International Epilepsy Congress – 2001 Epilepsia introduces on–line submission and reviewing in Paris with 5060 delegates 2001 24th International Epilepsy Congress – in Buenos Aires 2005 Bangladesh, China, Costa Rica, Cyprus, Kazakhstan, Nicaragua, Pakistan, 2001 Launch of phase 2 of the Global Campaign Against Epilepsy Singapore and the United Arab Emirates join the ILAE in Geneva 2005 Epilepsy Atlas published under the auspices of the Global 2001 Albania, Armenia, Arzerbaijan, Estonia, Honduras, Jamaica, Campaign Against Epilepsy Kyrgyzstan, Iraq, Lebanon, Malta, Malaysia, Nepal , Paraguay, Philippines, Qatar, Senegal, Syria, South Korea and Zimbabwe 2006 1st regional vice–president is elected – from the Asian and join the ILAE, making a total of 81 chapters Oceanian Region
    [Show full text]
  • The History of Neuroscience in Autobiography VOLUME 6 This Page Intentionally Left Blank the History of Neuroscience in Autobiography VOLUME 6
    The History of Neuroscience in Autobiography VOLUME 6 This page intentionally left blank The History of Neuroscience in Autobiography VOLUME 6 Edited by Larry R. Squire 1 2009 1 Oxford University Press, Inc., publishes works that further Oxford University’s objective of excellence in research, scholarship, and education. Oxford New York Auckland Cape Town Dar es Salaam Hong Kong Karachi Kuala Lumpur Madrid Melbourne Mexico City Nairobi New Delhi Shanghai Taipei Toronto With offi ces in Argentina Austria Brazil Chile Czech Republic France Greece Guatemala Hungary Italy Japan Poland Portugal Singapore South Korea Switzerland Thailand Turkey Ukraine Vietnam Copyright © 2009 by Society for Neuroscience Published by Oxford University Press, Inc. 198 Madison Avenue, New York, New York 10016 www.oup.com Oxford is a registered trademark of Oxford University Press All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of Oxford University Press. Library of Congress Control Number: 96070950 ISBN: 978–0–19–538010–1 1 3 5 7 9 8 6 4 2 Printed in the United States of America on acid-free paper Contents Previous Contributors vii Preface to Volume 1 ix Preface to Volume 6 xi Bernard W. Agranoff 1 Emilio Bizzi 32 Marian Cleeves Diamond 62 Charles G. Gross 96 Richard Held 158 Leslie L. Iversen 188 Masakazu Konishi 226 Lawrence Kruger 264 Susan E. Leeman 318 Vernon B. Mountcastle 342 Shigetada Nakanishi 382 Solomon H. Snyder 420 Nobuo Suga 480 Hans Thoenen 514 Index of Names This page intentionally left blank Previous Contributors Volume 1 Denise Albe-Fessard Herbert H.
    [Show full text]
  • Nobel Laureates in Physiology Or Medicine
    All Nobel Laureates in Physiology or Medicine 1901 Emil A. von Behring Germany ”for his work on serum therapy, especially its application against diphtheria, by which he has opened a new road in the domain of medical science and thereby placed in the hands of the physician a victorious weapon against illness and deaths” 1902 Sir Ronald Ross Great Britain ”for his work on malaria, by which he has shown how it enters the organism and thereby has laid the foundation for successful research on this disease and methods of combating it” 1903 Niels R. Finsen Denmark ”in recognition of his contribution to the treatment of diseases, especially lupus vulgaris, with concentrated light radiation, whereby he has opened a new avenue for medical science” 1904 Ivan P. Pavlov Russia ”in recognition of his work on the physiology of digestion, through which knowledge on vital aspects of the subject has been transformed and enlarged” 1905 Robert Koch Germany ”for his investigations and discoveries in relation to tuberculosis” 1906 Camillo Golgi Italy "in recognition of their work on the structure of the nervous system" Santiago Ramon y Cajal Spain 1907 Charles L. A. Laveran France "in recognition of his work on the role played by protozoa in causing diseases" 1908 Paul Ehrlich Germany "in recognition of their work on immunity" Elie Metchniko France 1909 Emil Theodor Kocher Switzerland "for his work on the physiology, pathology and surgery of the thyroid gland" 1910 Albrecht Kossel Germany "in recognition of the contributions to our knowledge of cell chemistry made through his work on proteins, including the nucleic substances" 1911 Allvar Gullstrand Sweden "for his work on the dioptrics of the eye" 1912 Alexis Carrel France "in recognition of his work on vascular suture and the transplantation of blood vessels and organs" 1913 Charles R.
    [Show full text]
  • Nobel Laureates Published In
    Nobel Laureates Published in Science has published the research of over 400 Laureates since the award’s inception in 1901! Award categories include Chemistry, Physics, and Medicine. Listed here are prize-winning authors from 1990 to the present, with the number of articles each Laureate published in Science. MEDICINE Articles CHEMISTRY Articles PHYSICS Articles 2015 2016 2014 William C. Campbell . 2 Ben Feringa —Netherlands........................5 Shuji Namakura—Japan .......................... 1 J. Fraser Stoddart—UK . 7 2014 2012 John O’Keefe—US...................................3 2015 Serge Haroche—France . 1 May-Britt Moser—Norway .......................11 Tomas Lindahl—US .................................4 David J. Wineland—US ............................12 Edvard I. Moser—Norway ........................11 Paul Modrich—US...................................4 Aziz Sancar—US.....................................7 2011 2013 Saul Perlmutter—US ............................... 1 2014 James E. Rothman—US ......................... 10 Brian P. Schmidt—US/Australia ................. 1 Eric Betzig—US ......................................9 Randy Schekman—US.............................5 Stefan W. Hell—Germany..........................6 2010 Thomas C. Südhof—Germany ..................13 William E. Moerner—US ...........................5 Andre Geim—Russia/UK..........................6 2012 Konstantin Novoselov—Russia/UK ............5 2013 Sir John B. Gurdon—UK . 1 Martin Karplas—Austria...........................4 2007 Shinya Yamanaka—Japan.........................3
    [Show full text]
  • The Molecular Wake-Up Call It Is 50 Years Since Arvid Carlsson Showed Dopamine to Be a Neurotransmitter
    NEWS FEATURE NATURE|Vol 447|24 May 2007 The molecular wake-up call It is 50 years since Arvid Carlsson showed dopamine to be a neurotransmitter. Alison Abbott profiles a chemical and its champion. hey were conscious but you wouldn’t know it: able to perceive the world around them but powerless to look Taround, sniff the air or to cry out. So when the young scientist injected them with a chemical called l-dopa, he witnessed what seemed to be a miracle. They stirred, opened their eyes and began roaming around as if nothing had happened. This may sound familiar from the book Awakenings1 — the true story of how, in 1963, the neurologist Oliver Sacks used l-dopa to spectacularly revive patients with sleeping sickness who had been ‘frozen’, speechless and motionless, for more than 40 years. But the unwritten and equally startling pre- quel took place in Lund, Sweden, several years earlier. The protagonists were rab- Catatonic rabbits were revived by bits; their saviour a young Swedish phar- dopamine in a 1957 experiment led macologist called Arvid Carlsson. by Arvid Carlsson. In his experiment, Carlsson showed that dopamine — the chemical manufac- embrace new techniques and fight tured from levodopa, or l-dopa — acts as for controversial ideas, as Carlsson a neurotransmitter in the brain, passing in Carlsson’s home has done throughout his career, remains essen- signals between neighbouring neurons. town of Gothenburg, Sweden, to cel- tial to success. “He was one of my heroes when Injection of l-dopa restored the propagation ebrate the 50th anniversary of his formative I was a young neurology resident,” says William of electrical signals in the brains of rabbits that paper on the awakened rabbits2.
    [Show full text]
  • List of Recent Winners of the Nobel Medicine 2 October 2016
    List of recent winners of the Nobel medicine 2 October 2016 Nobel judges at the Karolinska Institute in and Oliver Smithies Stockholm will announce the Nobel Prize in medicine on Monday on the heels of a scandal — 2006: Andrew Z. Fire and Craig C. Mello over a disgraced stem cell scientist that has rocked the prestigious institution. — 2005: Barry J. Marshall and J. Robin Warren Dr. Paolo Macchiarini, once considered a pioneer — 2004: Richard Axel and Linda B. Buck in windpipe transplants, was fired by Karolinska after being accused of falsifying his resume and — 2003: Paul C. Lauterbur and Sir Peter Mansfield misrepresenting his work. He denies wrongdoing. — 2002: Sydney Brenner, H. Robert Horvitz and Karolinska officials faced scathing criticism for how John E. Sulston they handled the Macchiarini case, and two members of the Nobel Assembly were dismissed — 2001: Leland H. Hartwell, Tim Hunt and Sir Paul amid concerns that the scandal at the institute M. Nurse would taint the Nobel Prize. — 2000: Arvid Carlsson, Paul Greengard and Eric R. The award, the first of this year's Nobel Prizes, will Kandel be announced Monday at 11:30 a.m. (0930 GMT). Here is a list of winners from the past 20 years. — 1999: Gunter Blobel ___ — 1998: Robert F. Furchgott, Louis J. Ignarro and Ferid Murad — 2015: William C. Campbell, Satoshi Omura and Tu Youyou. — 1997: Stanley B. Prusiner — 2014: John O'Keefe, May-Britt Moser and Edvard— 1996: Peter C. Doherty and Rolf M. Zinkernagel Moser. © 2016 The Associated Press. All rights reserved. — 2013: James E. Rothman, Randy W.
    [Show full text]
  • Nobel Laureates Published In
    Nobel Laureates Published in Science has published articles by Nobel Prize® Laureates since the award’s inception! Award categories include Chemistry, Physics, and Medicine. Listed here are prize winning authors from 1990 to the present, with the number of articles each laureate published in Science. Science is considered one of the world’s most prestigious scientific journals and is published by the American Association for the Advancement of Science (AAAS). CHEMISTRY MEDICINE Physics 2009 2009 2007 Venkatraman Ramakrishnan—UK ............10 Elizabeth H. Blackburn—US ................................6 Albert Fert—France ...............................................1 Thomas A. Steitz—US ............................................28 Carol W. Greider—US ..................................................1 Ada E. Yonath—Israel ..................................................1 Jack W. Szostak—US ...................................................9 2006 John C. Mather—US ............................................1 2008 2008 Osamu Shimomura—US ........................................7 Françoise Barré-Sinnoussi—Germany ........6 2005 Martin Chalfie—US .......................................................6 Luc Montagnier—France .....................................11 John L. Hall—US .....................................................3 Roger Y. Tsien—US ...................................................14 Harald zur Hausen—France ...................................2 Theodore W. Hänsch—Germany ................2 2007 2007 2004 Gerhard Ertl—Germany
    [Show full text]
  • 2019 Annual Report
    BRAIN & BEHAVIOR RESEARCH FOUNDATION 2019 ANNUAL REPORT Awarding research grants to develop improved treatments, cures, and methods of prevention for mental illness. BBRF is the world’s largest private funder of mental health research grants, supporting transformative discoveries in order to develop improved treatments, cures, and methods of prevention for our loved ones. CONTENTS Mission 4 BBRF Events 28 Leadership Letter 6 The Research Partners Program 42 Important Advancements 8 Team Up for Research 50 BBRF Scientific Council 12 2019 Donor Listing 52 2019 Leading Research Achievements 14 Getting the Word Out 76 BBRF Grants 18 Financial Summary 78 2019 Grants by Illness 20 The Research We Fund We invest in innovative research because we believe that only by pursuing the boldest and most ambitious ideas will we find better treatments, cures, and methods of prevention for mental illness. We are at the Forefront of Critical Discoveries Since 1987, the Brain & Behavior Research Foundation has awarded more than $408 million in grants that have led to discoveries that change the way we think about recovery. BBRF-funded research has contributed to: • FDA approval of the first rapid-acting antidepressants (esketamine and brexanalone) to alleviate severe depression symptoms within hours. • Dietary supplements for pregnant women to potentially help prevent subsequent mental illness in the child. • Development of Transcranial Magnetic Stimulation (TMS) and continued improvement of TMS and other non-invasive brain stimulation treatments for treatment-resistant depression and obsessive compulsive disorder. • Computer-guided training for cognitive remediation in people with schizophrenia. MISSION The Brain & Behavior Research Foundation is committed to alleviating the suffering caused by mental illness by awarding grants that will lead to advances and breakthroughs in scientific research.
    [Show full text]
  • List of Nobel Laureates 1
    List of Nobel laureates 1 List of Nobel laureates The Nobel Prizes (Swedish: Nobelpriset, Norwegian: Nobelprisen) are awarded annually by the Royal Swedish Academy of Sciences, the Swedish Academy, the Karolinska Institute, and the Norwegian Nobel Committee to individuals and organizations who make outstanding contributions in the fields of chemistry, physics, literature, peace, and physiology or medicine.[1] They were established by the 1895 will of Alfred Nobel, which dictates that the awards should be administered by the Nobel Foundation. Another prize, the Nobel Memorial Prize in Economic Sciences, was established in 1968 by the Sveriges Riksbank, the central bank of Sweden, for contributors to the field of economics.[2] Each prize is awarded by a separate committee; the Royal Swedish Academy of Sciences awards the Prizes in Physics, Chemistry, and Economics, the Karolinska Institute awards the Prize in Physiology or Medicine, and the Norwegian Nobel Committee awards the Prize in Peace.[3] Each recipient receives a medal, a diploma and a monetary award that has varied throughout the years.[2] In 1901, the recipients of the first Nobel Prizes were given 150,782 SEK, which is equal to 7,731,004 SEK in December 2007. In 2008, the winners were awarded a prize amount of 10,000,000 SEK.[4] The awards are presented in Stockholm in an annual ceremony on December 10, the anniversary of Nobel's death.[5] As of 2011, 826 individuals and 20 organizations have been awarded a Nobel Prize, including 69 winners of the Nobel Memorial Prize in Economic Sciences.[6] Four Nobel laureates were not permitted by their governments to accept the Nobel Prize.
    [Show full text]